Hand-out
Press Releases
January 7, 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year


